NCT00430937 is a Phase 3 clinical trial of Daptomycin in Skin Diseases, Infectious, sponsored by Novartis Pharmaceuticals.

Who is sponsoring NCT00430937?

NCT00430937 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT00430937?

Interventions in NCT00430937: Daptomycin, Vancomycin, Teicoplanin.

What condition does NCT00430937 study?

NCT00430937 studies Skin Diseases, Infectious, Soft Tissue Infections.

Is NCT00430937 still recruiting?

NCT00430937 is currently terminated. Last updated 10 July 2012.

Are results published for NCT00430937?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2012-07-10 · How we verify

NCT00430937

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Multicenter, Randomized, Assessor-Blind Study to Evaluate Efficacy and Safety of Daptomycin Versus Vancomycin or Teicoplanin for Treatment of Complicated Skin and Soft Tissue Infections (cSSTI)

Terminated Phase 3 Results posted Last updated 10 July 2012

What this trial tests

Phase 3 trial testing Daptomycin in Skin Diseases, Infectious in 194 participants. Terminated before completion.

Timeline

1 April 2006

Primary endpoint
1 March 2008

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	194
Start date	1 April 2006
Primary completion	1 March 2008

Drugs / interventions tested

Daptomycin (Daptomycin) — full drug profile →
Vancomycin (vancomycin) — full drug profile →
Teicoplanin — full drug profile →

Conditions studied

Skin Diseases, Infectious — all drugs for Skin Diseases, Infectious →
Soft Tissue Infections — all drugs for Soft Tissue Infections →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with Skin Diseases, Infectious or Soft Tissue Infections. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Clinical Success as Measured by Comparing the Participants Signs and Symptoms at the "Test of Cure" (TOC) Visit to Those Recorded at Study Baseline in the Clinically Evaluable Population.
Time frame: Baseline to TOC Visit (7-14 days after end of treatment) up to 4 weeks
Success: Total resolution of clinically significant signs and symptoms of the infection site (cure) or improvement to such a level that no further antibacterial therapy was required (improvement). Failure: Persistence or progression of signs and symptoms after at least 3 days of study therapy, or development of new signs and symptoms at the infection site, or concomitant or additional antibacteri

Sponsor's own description

This study evaluated the efficacy and safety of daptomycin compared to vancomycin or teicoplanin for the treatment of complicated skin and soft tissue infections

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Daptomycin

Trials testing the same drug.

NCT04983901 — PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN · Phase 2 · completed
NCT04775953 — DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia · Phase 2 · completed
NCT04277143 — A Pharmacokinetics Study of Daptomycin in Critically Ill Patients and Effects of Daptomycin on Kidney · unknown
NCT04434300 — Subcutaneous Daptomycin in Healthy Volunteers (DAPTOSC) · Phase 1 · completed
NCT03138733 — Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia · Phase 3 · completed

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00430937 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 10 July 2012

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00430937.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing